Endothelial C-Type Natriuretic Peptide is a Critical Regulator of Angiogenesis and Vascular Remodeling. by Bubb, KJ et al.
Bubb et al. (2018) 
1  
Endothelial C-type natriuretic peptide is a critical regulator of angiogenesis and 
vascular remodeling 
 
1,2#Kristen J Bubb PhD, 1#Aisah A Aubdool PhD, 1Amie J Moyes PhD, 3Sarah Lewis MD, 
1Jonathan P Drayton MD, 2Owen Tang PhD, 4Vedanta Mehta PhD, 4Ian C Zachary PhD, 
3David J Abraham PhD, 3Janice Tsui MD and 1*Adrian J Hobbs PhD 
 
1William Harvey Research Institute, Barts & The London School of Medicine & Dentistry, 
Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK, 
2University of Sydney, Kolling Institute of Medical Research, St Leonards, 2065, Australia, 
3Centre for Rheumatology and Connective Tissue Diseases, University College London 
Medical School, Royal Free Campus, London, NW3 2PF, UK, and 4Centre for 
Cardiovascular Biology and Medicine, Division of Medicine, The Rayne Building, University 
College London, London WC1E 6JJ, UK. 
 
*Author for correspondence at the above address 
Tel: +44 (0)207 882 5778, Fax: +44 (0)207 882 8403, Email: a.j.hobbs@qmul.ac.uk 
 
#Contributed equally to this work 
 
Running title: CNP regulates angiogenesis and vascular remodeling 
 
Word count: 5100 
  
Bubb et al. (2018) 
2  
ABSTRACT 
 Background: Angiogenesis and vascular remodeling are complementary, innate 
responses to ischemic cardiovascular events, including peripheral artery disease (PAD) and 
myocardial infarction, which restore tissue blood supply and oxygenation; the endothelium 
plays a critical function in these intrinsic protective processes. C-type natriuretic peptide 
(CNP) is a fundamental endothelial signaling species that coordinates vascular 
homeostasis. Herein, we sought to delineate a central role for CNP in angiogenesis and 
vascular remodeling in response to ischemia. 
 Methods: The in vitro angiogenic capacity of CNP was examined in pulmonary 
microvascular endothelial cells (PMEC) and aortic rings isolated from wild type (WT), 
endothelium-specific CNP knockout (ecCNP-/-), and global natriuretic peptide receptor 
(NPR)-B-/- and NPR-C-/- animals, and in human umbilical vein endothelial cells (HUVEC). 
These studies were complemented by in vivo investigation of neovascularization and 
vascular remodeling following ischemia or vessel injury, and CNP/NPR-C expression & 
localization in tissue from patients with PAD. 
 Results: Clinical vascular ischemia is associated with reduced levels of CNP and its 
cognate NPR-C. Moreover, genetic or pharmacological inhibition of CNP and NPR-C, but 
not NPR-B, reduces the angiogenic potential of PMEC, HUVEC and isolated vessels ex 
vivo. Angiogenesis and remodeling are impaired in vivo in ecCNP-/- and NPR-C-/-, but not 
NPR-B-/-, mice; the detrimental phenotype caused by genetic deletion of endothelial CNP, 
but not NPR-C, can be rescued by pharmacological administration of CNP. The pro-
angiogenic effect of CNP/NPR-C is dependent on activation of Gi, ERK1/2 and PI3Kγ/Akt at 
a molecular level. 
 Conclusions: These data define a central (patho)physiological role for CNP in 
angiogenesis and vascular remodeling in response to ischemia and provide the rationale for 
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pharmacological activation of NPR-C as an innovative approach to treating PAD and 
ischemic cardiovascular disorders. 
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What is new? 
 Angiogenesis and arteriogenesis are harmonized responses to ischemia (e.g. peripheral 
arterial disease and myocardial infarction) which restore tissue perfusion. 
 This study defines a central (patho)physiological role for endothelium-derived C-type 
natriuretic peptide (CNP), via activation of cognate natriuretic peptide receptor (NPR)-C, 
in angiogenesis and vascular remodeling. 
 Moreover, the work demonstrates the therapeutic utility of pharmacologically targeting 
NPR-C to restore deficits in these processes following ischemia and injury. 
 
What are the clinical implications? 
 Previous approaches aimed at facilitating angiogenesis in peripheral arterial disease 
have proven ineffective in clinical trials, the only currently effective management is 
surgery. 
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 The novel signaling system we have identified offers promise to radically improve and 
resolve the poor perfusion in PAD patients, reducing the need for invasive intervention 
and amputation. 
 Targeting the CNP/NPR-C pathway may therefore offer a tangible pharmacological 
approach to improve PAD and other ischemic cardiovascular disorders. 
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INTRODUCTION 
The morbidity and mortality associated with peripheral arterial disease (PAD) is an 
expanding unmet medical need as a consequence of the ageing population and growing 
prevalence of metabolic disorders1, 2. PAD affects more than 200 million individuals 
worldwide and typically manifests as intermittent claudication but often progresses to, or 
even presents as, critical limb ischemia (CLI) characterized by pain, ulceration and 
gangrene; many patients face amputation and early death1, 2. Pathology is triggered by 
atherosclerotic vascular occlusions and is underpinned by an insufficient angiogenic 
(hypoxia-triggered de novo blood vessel formation) and arteriogenic (shear stress-induced 
remodeling of the collateral network) response; compensatory and complementary 
mechanisms invoked to reinstate blood supply to the ischemic tissue3. A central pathway 
coordinating both processes is driven by vascular endothelial growth factor (VEGF)-A4, 
which pre-clinical studies indicated was a potential treatment for PAD5. However, large-
scale clinical trials using VEGF-A to promote angiogenesis and/or arteriogenesis in PAD 
and CLI patients have proven disappointing6-8. Therefore, delineation of the mechanisms 
and signaling pathways that underlie these intrinsic, restorative pathways are critical if the 
therapeutic potential of a pro-angiogenic strategy is to be harnessed. 
The endothelium is pivotal in triggering angiogenesis, vascular remodeling and 
minimizing functional deficit following ischemia9. Endothelium-derived C-type natriuretic 
peptide (CNP) plays a fundamental role in regulating vascular homeostasis10-12; CNP 
controls local blood flow in the resistance vasculature and systemic blood pressure, 
reduces the reactivity of leukocytes and platelets, and prevents the development of 
atherogenesis and aneurysm. Several facets of CNP biology suggest it may play a central 
role in angiogenesis. For instance, two of the primary stimuli for CNP release from 
endothelial cells are shear stress13 and TGFβ14, both of which are well-validated triggers for 
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angiogenesis & arteriogenesis. In addition, HIF-1α, a fundamental driver of the ischemic 
angiogenic response, is a potent enhancer of natriuretic peptide expression, particularly in 
cardiomyocytes15. Our previous studies revealed that pulmonary microvascular endothelial 
cells from endothelium-specific CNP-/- (ecCNP-/-) and global NPR-C-/- mice proliferate 
significantly more slowly compared to wild type (WT) cells16, implying that CNP has a 
physiological role in regulating growth. The peptide also slows neointimal hyperplasia and 
promotes re-endothelialisation in vein grafts17, in damaged carotid arteries18, and following 
balloon angioplasty19, 20. CNP also maintains capillary density after myocardial infarction21 
and hind-limb ischemia22. Whilst these observations intimate that pharmacological 
administration of CNP may promote arteriogenesis & angiogenesis, previous work has 
reported that CNP blocks VEGF signaling to attenuate angiogenesis in vitro23, and reduces 
sponge implant neovascularisation in vivo24, demonstrating the function of CNP in this 
setting remains unclear and requires further investigation. Moreover, there is no evidence 
demonstrating that endothelium-derived CNP either directly stimulates angiogenesis, or 
triggers endothelial cell processes critical for angiogenesis. Therefore, given recent findings 
showing an important role for CNP in vascular homeostasis10-12, we sought to investigate 





All murine studies conformed to the UK Animals (Scientific Procedures) Act of 1986 
and had approval from the local Animal Welfare and Ethical Review Body (AWERB) within 
Bart’s and The London School of Medicine. The human tissue studies were permitted under 
Local Research Ethics Committee decision 16/WA/0198 (IRAS project ID: 193340) with 
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informed patient consent. The authors declare that all supporting data are available within 
the article (and its online Supplemental files). 
 
Endothelial 3D-tube formation assay 
Primary murine pulmonary endothelial cells (PMECs) were isolated as we have 
described previously16. PMEC were re-suspended in diluted ECGM (1:3 in DMEM/F12) and 
plated on 15 mg/mL reduced-growth factor extracellular matrix (Cultrex, Trevigen, USA) at 
a density of 1.75 × 105 cells/cm2. Tubule formation was determined by measuring branch 
number and length using NIH Image J software, 2, 4 and 6 h after treatment with CNP (1 
nM to 1 µM, GenScript, USA) or VEGF (30 ng/mL, Pre-protech, USA). 
Tubule formation in HUVEC was measured following treatment with CNP (1 nM) or 
ANP (10 nM) in the absence or presence of selective NPR-C antagonist M372049 (10 µM), 
the selective PI3Kγ inhibitor AS605240 (100 nM; Sigma), or the selective PKG blocker 
KT5283 (2 μM; Sigma) over a 16 h period. A cohort of cells was transfected using 
lipofectamine 2000 (Thermofisher Scientific) with either non-specific siRNA (Mission 
Control, Sigma Aldrich), NPR-B- or NPR-C- specific siRNA (Sigma Aldrich) and were 
treated with CNP or the selective NPR-C agonist, cANF4-23 (2 nM). Silencing of NPR-B and 
NPR-C was confirmed at the mRNA and protein level using RT-PCR and immunoblot 
(Supplemental Figure 1A-C). 
 
Cell migration assay 
Endothelial cells were plated in gelatin-coated wells of a 96 well plate (Corning® 
Biocoat, UK) at a density of 1.75 × 105 cells/cm2 and left to reach confluence. A scratch was 
performed using a 10 μL sterile pipette and images were taken at regular intervals over a 
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24 h period to monitor scratch closure. Cell populations were treated with CNP (1 nM to 1 
µM) or VEGF (30 ng/mL). 
 
Aortic sprouting assay 
Mice were killed by cervical dislocation and thoracic aortas were removed, trimmed 
of all extraneous tissue and flushed with media via the lumen to remove all blood. Rings of 
~0.5 mm were cut and embedded 1 mg/mL collagen matrix (type 1 rat tail, Millipore, 
Germany) and incubated for 1 h at 37°C. Opti-MEM + Glutamax media (Opti-MEM, Gibco, 
UK) containing 2.5% bovine serum (Gibco, UK), 50 U/mL penicillin and 0.5 mg/mL 
streptomycin (Sigma-Aldrich, UK) and either CNP (1 nM to 1 µM) or VEGF (30 ng/mL) or 
was added to the wells. Interventions were refreshed every 2 days and images of sprouting 
aortae were obtained after 7 days. 
 
Matrigel plug neovascularization 
Mice were injected subcutaneously with 15 mg/mL reduced-growth factor 
extracellular matrix (Cultrex, Trevigen, USA) containing 30 ng/mL VEGF (Pre-protech, 
USA) and 50 U Heparin (Pfizer, UK), which formed a solid ‘plug’ at body temperature. Plugs 
were extracted after 14 days and homogenized in 0.5 mL of cell lysis buffer and centrifuged 
at 6000 x g at 4 °C for 60 min. Hemoglobin was detected at 400 nm wavelength, using a 
colorimetric assay (Sigma-Aldrich, UK). Histological analysis of fixed and paraffin 
embedded matrigel plugs was performed using hematoxylin and eosin (H&E) and isolectin 
B4 staining. 
 
Hindlimb ischemia (HLI) 
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Mice were anaesthetized with 1.5-2% isoflurane vaporized in oxygen, placed on a 
heated blanket to maintain body temperature and a small incision (~10 mm) was made in 
the hindlimb skin directly over the femoral vasculature. All mice received pre-operative 
analgesia (buprenorphine, 0.1mg/kg, Vetergesic, Alstoe Animal health). A portion of the 
femoral artery was exposed via a 2 cm incision and two ligations were performed using 
eight nylon sutures, first distal to the origin of the profunda femoris artery and second 
proximal to the saphenous artery. The femoral artery was then excised between the ligation 
sites and the skin was closed with non-continuous absorbable suture. Non-invasive laser 
Doppler imaging (Moor LDI2, Moor Instruments Ltd, UK) was used to assess hindlimb blood 
flow at baseline and immediately after undergoing HLI, with subsequent imaging at day 3, 
7, 14, 21 and 28 post HLI. The rate of reperfusion in the hindlimb was calculated as a ratio 
of blood flow in the ipsilateral ischemic versus non-ischemic in the contralateral limb. In 
some experiments, mice were implanted with osmotic mini-pumps (1002; Alzet) containing 
CNP (0.2mg/kg/day) at day 0 to explore if any phenotype produced by gene KO could be 
reversed by pharmacological application of the peptide. At the end of the study (Day 28), 
mice were briefly anaesthetized with isoflurane and blood was collected via cardiac 
puncture. Mice were culled by cervical dislocation and the gastrocnemius muscle from each 
leg was harvested for post analysis. In some experiments, the gastrocnemius muscle from 
each leg was harvested at day 3 and day 7 post HLI from WT mice, treated with an RNA 
stabilizer (RNAlater, Sigma, UK) and stored at -20°C before RNA isolation. 
 
Carotid injury 
Mice were anaesthetized using 1.5-2 % isoflurane in oxygen. Left internal carotid 
arteries were exposed and isolated from surrounding nerves and tissue. A 0.35 mm wire 
catheter was introduced via a small incision and inserted and extracted repeatedly, 3 times, 
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over ~15 mm length of vessel, to remove the endothelial cell layer. Vessels were then and 
skin sutured using sterile 6-0 silk and mice allowed to recover. Mice were given 
buprenorphine (0.1 mg/kg) at the beginning of surgery for management of post-surgical 
pain. After 14 days, mice were anaesthetized with sodium pentobarbital (100 mg/mL). 
Blood was cleared using phosphate buffered saline, and mice were then perfusion fixed 
with 4% paraformaldehyde at 100 mmHg. Injured left and control right carotid arteries were 
dissected out and embedded in paraffin. 4 μm sections every 500 μm were cut and stained 
with H&E and α-smooth muscle actin (1:5000) for histological analysis. Vessel dimensions 
were measured using Image J analysis after calibration with a micrometer on H&E stained 
sections and intimal-media thickness ratio was calculated. 
 
Cutaneous wound healing 
The rate of skin wound closure following injury was determined using a cutaneous 
wound healing model. Mice were anesthetized with 1.5-2 % isoflurane and the dorsal skin 
was shaved and cleaned with alcohol. Per mouse, one bilateral full-thickness skin wound 
were created, using a sterile 3 mm biopsy punch on the dorsorostral back skin without 
injuring the underlying muscle. Wounds were digitally photographed at 0, 4, and 7 days 
after injury using a digital camera (Sony Europe Limited, Weybridge, UK). 
 
Protein and mRNA quantification and immunohistochemistry 
 These were conducted according to standard protocols. Further information can be 
found in the Supplemental Information and Supplemental Table 1. 
 
Data analysis 
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 Results are expressed as mean ± s.e.mean, and the n value denotes the number of 
animals or independent experiments per group. Statistical analyses were performed 
(GraphPad Prism version 6; GraphPad, La Jolla, CA, USA) using Student’s t-test, one-way 
or two-way ANOVA with Bonferroni post hoc tests as appropriate. 
 
RESULTS 
Expression of CNP and NPR-C are downregulated in human CLI patients 
Expression of VEGF-A and VEGF receptor 2 (VEGFR2) mRNA was significantly 
reduced whereas hypoxia-inducible factor 1α (HIF-1α), apoptosis regulator Bcl-2 associated 
X protein (Bax), vascular cell adhesion protein-1 (VCAM-1), interleukin-6 (IL-6) and C-C 
Motif Chemokine Ligand 2 (CCL2) mRNA were all elevated in gastrocnemius muscle 
biopsies from CLI patients in comparison to healthy controls, commensurate with a 
compromised angiogenic, re-modelling environment25, 26 (Supplemental Figure 2A). 
Evidence that CNP/NPR-C signalling might be critical to a pro-angiogenic, pro-arteriogenic 
host defense response to ischemia was provided by a parallel reduction in both CNP 
(mRNA) and NPR-C (mRNA & protein) levels in CLI tissue (NPR-B mRNA expression was 
also reduced; Figure 1A & Supplemental Figure 3A). Furthermore, NPR-C protein 
expression, which co-localized with the cell membrane (WGA-positive) and vascular 
endothelium (CD31-positive) was markedly reduced around both the myofibers (Figure 1B) 
and blood vessels (Figure 1C) in gastrocnemius samples of CLI patients compared to 
healthy controls.  
 
CNP promotes angiogenesis in human and murine endothelial cells via NPR-C 
Accordingly, exogenous CNP increased the rate of migration of HUVECs in a 
concentration-dependent manner with the highest concentration producing a response with 
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a similar time-course and magnitude to the archetypal pro-angiogenic mediator, VEGF 
(Figure 1D-E). Pharmacological administration of CNP also promoted tubule formation in 
HUVEC with a maximal effect commensurate with that produced by VEGF (Figure 1F). 
Combination of CNP and VEGF result in a modest additive effect on tubule forming activity 
across genotypes (Supplemental Figure 4A), suggesting the two mediators are not inter-
dependent. In order to substantiate the thesis that NPR-C activation underpins the pro-
angiogenic action of CNP, genetic and pharmacological deletion of NPR-C was employed 
in HUVEC to demonstrate an anti-angiogenic phenotype. Indeed, in the presence of both 
the selective NPR-C antagonist M237204927 (Figure 1G-H) and siRNA knockdown of NPR-
C (Figure 1I & Supplemental Figure 1A-B), the tubule formation driven by CNP was 
abrogated. Furthermore, siRNA knockdown of NPR-B did not alter the pro-angiogenic 
capacity of CNP (Supplemental Figure 1C-D). The selective NPR-C agonist27, cANF4-23, 
also produced an essentially identical increase in tubule formation that was sensitive to 
blockade by M372049 (Supplemental Figure 4B). These data establish the pro-angiogenic 
capacity of CNP-NPR-C signaling in human endothelial cells and provide direct evidence 
that such a pathway is downregulated in human PAD/CLI. Interestingly, increases in tubule 
formation driven by ANP were not sensitive to blockade by M372049 (Supplemental 
Figure 5), intimating that this member of the natriuretic peptide family is unable to trigger 
angiogenic behavior in endothelial cells via NPR-C; this finding fits well with previous work 
identifying NPR-A/cGMP/PKGI as the key pathway underpinning ANP/BNP-driven 
revascularization following ischemia22, 28. 
To reiterate the importance of endothelium-derived CNP in angiogenic signalling, 
murine PMECs were isolated from ecCNP-/- animals, in which CNP is conditionally deleted 
in endothelial cells, and from WT littermates and used to investigate in vitro migration and 
tubule formation. Consistent with the HUVEC data, CNP promoted migration in a scratch 
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closure assay in WT murine PMECs in a concentration-dependent manner and with a 
similar maximal activity to VEGF (Figure 2A & Supplemental Figure 6). The inherent 
migratory capacity of PMECs was reduced subtly in cells from ecCNP-/- mice compared to 
WT littermates (Figure 2B). However, exogenous CNP was able to increase the rate of 
scratch closure in cells from both genotypes to a similar extent to that observed in HUVEC 
(Figure 2A,C). Of note, the relative increase in migration in PMECs from ecCNP-/- mice was 
greater than that in WT cells, suggesting a sensitization of the underlying signaling 
pathway. PMECs from mice with global deletion of NPR-B or NPR-C were utilized to 
confirm the NPR subtype underlying the actions of CNP on endothelial migration and tube 
formation. PMECs from NPR-B-/- mice had an intrinsic migratory capacity equivalent to WT 
(Figure 2D), whereas PMECs from NPR-C-/- animals exhibited a significantly slower scratch 
closure (Figure 2D). Whilst pharmacological addition of CNP promoted endothelial 
migration in NPR-B-/- cells (Figure 2E), it had no significant effect in NPR-C-/- cells (Figure 
2F). This receptor-specific activity was recapitulated in assays of endothelial tubule 
formation, in which ecCNP-/- and NPR-C-/- cells displayed significantly impaired intrinsic 
tubule-forming activity compared to cells from WT and NPR-B-/- mice (Figure 2G-H). 
Likewise, the ability of exogenous CNP to stimulate tubule development was only apparent 
in WT, ecCNP-/- and NPR-B-/- cells, but was abrogated in cells from NPR-C-/- mice (Figure 
2G-H). These findings corroborate a fundamental role for endothelial CNP-NPR-C signaling 
in stimulating cellular functions essential for angiogenesis. 
 
De novo sprouting ex vivo and neovascularization in vivo is diminished in vessels 
lacking either endothelial CNP or NPR-C 
A more complex ex vivo model of angiogenic sprouting was subsequently employed 
to verify this novel angiogenic role for endothelium-derived CNP. Aortic sprouting in vessel 
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segments from WT animals was potentiated in a concentration-dependent manner by 
treatment with CNP with a time-course and response magnitude equivalent to those of 
VEGF (Figure 3A-B). Furthermore, spontaneous sprouting was overtly impaired in aortic 
rings from ecCNP-/- and NPR-C-/- mice in comparison to WT animals (Figure 3C). In sharp 
contrast, in vessel segments from NPR-B-/- mice, de novo sprouting was similar to that in 
WT aortic rings (Figure 3C). The requirement of NPR-C activation for the pro-angiogenic 
action of CNP in this assay was demonstrated by the failure of exogenous CNP to promote 
aortic sprouting in NPR-C-/- aortic rings, as compared with vessels from ecCNP-/- and NPR-
B-/- mice (Figure 3C). These data dovetail well with the rudimentary in vitro models (above) 
establishing that CNP-NPR-C signaling is critical to the angiogenic potential of the 
endothelium. 
Next, we investigated the influence of CNP on neovascularization in vivo using an 
assay in which subcutaneously implanted matrigel plugs exhibit a significant increase in de 
novo vessel formation and hemoglobin content (as an index of mature, perfused 
vasculature; Figure 3D-F). In accord with our data from aortic ring assays, CNP caused a 
striking stimulation of neovascularization in matrigel plugs implanted in WT, ecCNP-/- and 
NPR-B-/- mice but had no significant effect on angiogenesis in NPR-C-/- mice (Figure 3D-F 
& Supplemental Figure 7). These findings taken together with our data from cell-based 
and aortic ring assays provide strong evidence that CNP potently promotes angiogenesis 
specifically via the NPR-C subtype. 
 
CNP governs angiogenesis via NPR-C-dependent activation of ERK1/2 and 
Akt/Protein kinase B 
We have previously reported that NPR-C-dependent ERK1/2 phosphorylation is key 
to augmenting CNP-driven endothelial cell proliferation16. In accord, we investigated if a 
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similar transduction pathway is responsible for the angiogenic actions of CNP. The ability of 
exogenous CNP to trigger tubule formation in PMECs and aortae from WT animals was 
significantly attenuated by the selective ERK1/2 inhibitor, PD98059 (Figure 4A-B). The 
functional blockade by PD98059 was paralleled by a reduced ERK1/2 phosphorylation in 
response to CNP (Figure 4C). Endothelium-derived CNP was also required for basal 
ERK1/2 activation since PMEC from ecCNP-/- mice exhibited a significantly lower basal 
ERK1/2 phosphorylation compared to WT controls (Figure 4D), an effect that was fully 
rescued by addition of exogenous CNP, which stimulated ERK1/2 activation to a similar 
extent in WT and ecCNP-/- cells (Figure 4D). The role of NPR-C in conveying CNP 
angiogenic signaling was investigated using the selective NPR-C antagonist, M372049. 
Treatment with M372049 completely inhibited CNP-induced ERK1/2 activation in WT 
PMEC (Figure 4E). The mechanism linking NPR-C activation with ERK1/2 phosphorylation 
was examined with the use of the Gi-blocker pertussis toxin (PTx). As shown in Figure 4F, 
PTx strongly inhibited the ability of CNP to trigger ERK1/2 phosphorylation. We next 
investigated the role of the phosphoinositide 3-kinase (PI3K)/Akt (protein kinase B, PKB) 
pathway, which is essential to the migratory capacity of endothelial cells29. Here, the ability 
of CNP to promote endothelial tubule formation and aortic sprouting was blocked in the 
presence of the selective PI3K inhibitor wortmannin (Figure 4G-H). In addition, studies with 
the selective inhibitor AS605240 revealed that, specifically, PI3Kγ activation is a 
prerequisite for CNP-driven tubule formation and aortic sprouting (Supplemental Figure 
8A-B). Basal Akt/PKB phosphorylation was also significantly reduced in endothelial cells 
from ecCNP-/- and NPR-C-/- mice, but increased by incubation with CNP (Figure 4I). Finally, 
to rule out a role for NPR-B/cGMP signalling in the pro-angiogenic actions of CNP, tubule 
formation and aortic sprouting were investigated in the presence of the PKG inhibitor 
KT5823; in this setting, CNP-facilitated responses were unchanged (Supplemental Figure 
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8C-D). In concert, these observations establish that CNP-NPR-C-Gi coupling activates 
ERK1/2 and PI3Kγ/Akt/PKB signaling to promote angiogenesis, similar to the downstream 
pathways activated by VEGF and other well-established pro-angiogenic mediators3. These 
data are also consistent with previous reports linking NPR-C activation with Gi-signaling in 
the vasculature30. 
 
Restoration of blood flow following hindlimb ischemia is impaired by loss of 
endothelium-derived CNP but can be reversed by targeting NPR-C pharmacologically 
We utilized a well-established in vivo model of CLI to verify that endothelium-derived 
CNP, via NPR-C activation, is a prerequisite for optimal engagement of restorative 
angiogenic and arteriogenic pathways following pathological ischemia in vivo. Following 
unilateral ligation and excision of the femoral artery (hindlimb ischemia, HLI), mice undergo 
a pronounced remodeling to restore an adequate blood supply that supports essentially 
complete recovery (i.e. perfusion, motor function) over 28 days. Consistent with the findings 
in human tissue, the expression of both CNP and VEGF-A mRNA were reduced, with a 
marked increase in HIF-1α, Bax, VCAM-1, IL-6 and CCL2 in the ischemic gastrocnemius 
muscle at day 3 following HLI compared to the non-ischemic tissue in WT mice, with a 
subsequent increase in expression at day 7 (Figure 5A & Supplemental Figure 2B-C). 
ecCNP-/- mice exhibited a significantly impaired recovery following HLI in terms of perfusion 
(Figure 5B-C & Supplemental Figure 9A), blood vessel density (i.e. capillary/myofiber 
ratio; Figure 5D-E), fibrosis (i.e. collagen deposition; Figure 5F-G), and regeneration of 
muscle fibers (Figure 5H-I). This adverse phenotype in ecCNP-/- animals could be rescued 
by pharmacological administration of CNP (Figure 5B-I). Indeed, exogenous CNP 
improved indices of injury in WT mice implying that therapeutic targeting of the CNP-NPR-C 
pathway is likely to be of benefit above and beyond any endogenous signaling (paralleling 
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observations in PMEC where CNP-stimulated migration in ecCNP-/- was greater than that in 
WT). NPR-C mRNA and protein expression followed an identical temporal profile to CNP 
and VEGF-A, with an initial reduction (Day 3) followed by a significant increase (Day 7; 
Figure 6A & Supplemental Figures 2B-C & 3B), suggesting the expression of CNP-NPR-
C signalling is coordinated with the angiogenic response. However, NPR-C-/- mice 
presented with an overly more injurious phenotype after being subjected to HLI (Figure 6B-
I). Significantly, in sharp contrast to ecCNP-/- animals, pharmacological administration of 
CNP did not rescue phenotype in NPR-C-/- mice (Figure 6B-I & Supplemental Figure 9B). 
These data substantiate a pro-angiogenic, pro-remodeling function for endothelium-derived 
CNP in vivo and verify that activation of NPR-C underpins this process. Moreover, 
strategies aimed at pharmacologically activating NPR-C are likely to be of benefit in CLI 
patients. 
 
Reponses to vessel injury and wound healing in vivo are impaired in ecCNP-/- and 
NPR-C-/- mice 
In order to demonstrate a more widespread role for endothelial CNP in the host 
defense response to injury, we utilized two further independent, etiologically-distinct pre-
clinical models. First, we examined the remodeling in wire-injured murine carotid arteries 
(akin to percutaneous coronary intervention, PCI). In this setting, WT mice exhibited a 
typical, marked intimal hyperplasia following injury that was significantly exacerbated in 
ecCNP-/- and NPR-C-/- animals (Figure 7A-C). Indeed, the intimal thickening was 
particularly pronounced in NPR-C-/- mice, with almost complete occlusion of the vessel 
following injury (Figure 7C). Second, we investigated cutaneous wound healing following a 
biopsy on the dorsal skin. Here, wound closure was essentially complete in WT animals 
after 7 days (Figure 7D-G). However, this reparative process was markedly delayed in both 
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ecCNP-/- (Figure 7D-E) and NPR-C-/- mice (Figure 7F-G). These observations support the 
conclusion that CNP-NPR-C signaling has an important role in the tissue repair responses 




Ischemic cardiovascular disease, typified by PAD and CLI, MI and stroke, represents 
a major cause of global morbidity and mortality31. Restoration of adequate blood supply to 
hypoxic tissue, via complementary angiogenic and arteriogenic mechanisms, in response to 
ischemia is decisive for both host repair and therapeutic intervention. Previous attempts to 
harness these endogenous corrective pathways to improve outcome in PAD have focused 
primarily on promoting the actions of VEGF, yet these strategies have proven largely 
ineffective clinically, whether cell-, gene- or small-molecule- based6-8. Herein, we establish 
a previously undefined role for endothelium-derived CNP in angiogenesis and vascular 
remodeling. This critical function is dependent on activation of NPR-C and, via Gi-coupling, 
stimulation of the classical ERK1/2 and Akt/protein kinase B pathways that are harnessed 
by many factors promoting endothelial proliferation, migration and survival, including 
VEGF3, 32. Clinical evidence utilizing gastrocnemius muscle biopsies from CLI patients 
confirmed that expression of CNP and NPR-C is down-regulated, matching that observed at 
the earliest timepoints following HLI in the experimental model; yet mice are able to up-
regulate CNP and NPR-C expression to coincide with the angiogenic and arteriogenic 
response to ischemia. Diminution of CNP/NPR-C signalling in CLI may therefore underpin 
the inability to promote compensatory angiogenesis and vascular remodeling to maintain 
appropriate blood supply. However, targeting this pathway pharmacologically facilitates 
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angiogenesis and vascular remodeling, implying therapeutic approaches triggering NPR-C 
activation are likely to be of benefit in PAD/CLI and other ischemic disorders including MI. 
 Endothelium-derived CNP plays a fundamental role in regulating vascular function 
local blood flow, systemic blood pressure and the reactivity of circulating leukocytes and 
platelets10-12. Previous work has also suggested that this peptide contributes to the 
maintenance of blood vessel integrity and response to injury17-22. The signaling pathway(s) 
underpinning these vasoprotective functions of CNP remain unresolved. In terms of 
endothelial and vascular smooth muscle cell hyperplasia both cognate receptors, NPR-B 
and NPR-C, have been implicated33. However, in the present study, cells and tissues 
isolated from NPR-B-/- mice behaved in an identical fashion to WT in complementary in vitro 
and in vivo models of angiogenesis, whether in terms of intrinsic activity or in response to 
exogenous CNP; the pro-angiogenic effects of CNP in vitro were also insensitive to PKG 
inhibition. These findings demonstrate that NPR-B-triggered cGMP formation is unlikely to 
underlie the restorative capacity of CNP. Rather, genetic deletion of NPR-C produced an 
identical anti-angiogenic, anti-arteriogenic phenotype, both in vitro and in vivo, akin to that 
observed in mice lacking endothelium-derived CNP. This NPR-C-dependency adds to the 
growing number of physiological signaling roles of this G-protein coupled receptor 
traditionally thought solely to clear natriuretic peptides from the circulation34. Evidence now 
supports the conclusion that NPR-C is a cellular transduction trigger in the cardiovascular 
system, regulating diverse processes including cell growth16, oxidative stress35 and SA 
node conduction36. Moreover, Gi-coupling appears to mediate the majority of these 
actions30. Herein, we show that the pro-angiogenic effects of CNP, driven through NPR-C 
activation, are also Gi-dependent and involve signaling via both ERK1/2 and 
PI3Kγ/Akt/Protein kinase B; pathways well-established to synchronize angiogenesis & 
arteriogenesis3, 37 (Supplemental Figure 10). These observations fit well with the profile of 
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CNP and NPR-C expression in response to HLI (herein and 38), first falling and then 
increasing in a temporal manner that aligns with the restoration of blood flow and influence 
of VEGF, and thereby provide new mechanistic insight into the vasoprotective role of this 
receptor. Intriguingly, the loss of this protective phenotype observed in vitro, and to some 
extent in vivo, appeared to be more severe in global NPR-C-/- cells and tissues in 
comparison to those from ecCNP-/- mice. This differential activity may stem, in part, from an 
incomplete deletion of CNP from endothelial cells in the transgenic strain employed 
(~80%10) but may also originate from loss of constitutive receptor activity, a characteristic of 
GPCRs, in NPR-C-/- animals. Whether NPR-A/cGMP/PKGI signalling in response to ANP 
and/or BNP, which is established to promote revascularization following ischemia 22, 28, 
might offset the loss of CNP/NPR-C signalling remains to be determined. However, the anti-
angiogenic consequence of NPR-C deletion implies that increased activity of ANP/BNP 
(acting via NPR-A/cGMP/PKGI) resulting from elimination of the clearance capacity of NPR-
C is not sufficient to compensate overtly. Cursory investigation herein suggests that ANP is 
also unable to exert a similar pro-angiogenic effect via NPR-C. 
Additionally, we demonstrate clear therapeutic potential for pharmacologically 
activating NPR-C in PAD and other ischemic cardiovascular disorders. Administration of 
CNP (i.e. an NPR-C agonist) is able to significantly improve revascularization in vivo 
following ischemia, and the multi-faceted nature of this protective influence was highlighted 
by improvement in several indices of disease severity including improved leg and paw 
perfusion, increased vessel density, reduced fibrosis and accelerated myofibre 
regeneration. In the setting of PAD/CLI, the anti-leukocyte and anti-platelet actions of 
endothelial-derived CNP (via NPR-C)10 will proffer an additional level of protection from 
prospective atherosclerotic occlusion and represent additional therapeutic value. One 
possible caveat is the diminished NPR-C expression observed in amputated limbs from CLI 
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patients, which might limit efficacy of CNP/NPR-C-based treatments. However, at initial 
stages of PAD (e.g. onset of claudication) the components of the signalling pathway are 
likely to be expressed at a higher level, advocating early intervention. Moreover, the human 
CLI tissue was derived from extensively necrotic areas and it is conceivable that in the 
border region between healthy and diseased limb NPR-C expression is higher and 
therefore more tractable in terms of therapy (comparable to day 7 following HLI). Indeed, 
herein CNP delivery in the murine model was initiated at the nadir of NPR-C expression 
which matches that in CLI tissue. Regardless, pharmacological administration of CNP is 
incredibly effective at restoring blood flow, providing proof-of-concept that this strategy 
might be effective in CLI patients. 
Interestingly, there appears to be a reciprocal relationship between CNP and VEGF 
in the regulation of angiogenesis. VEGF inhibits CNP secretion from endothelial cells39 
whilst CNP (and other natriuretic peptides) have been reported to inhibit VEGF 
production40. Whether this represents temporal and/or spatial feedback communication 
between the parallel pathways remains to be explored, but a linking mechanism may 
involve TGFβ1 signaling, which is key to tissue repair following ischemia, since both CNP 
and VEGF have TGFβ1-responsive promoters41. A further common mechanism of 
regulation is likely provided by HIF-1α, which is known to be a key inducer of VEGF 
transcription (in addition to its downstream signaling components)42, and which also 
upregulates natriuretic peptide expression15. Indeed, the Nppc (CNP) promoter region 
contains several hypoxia response elements (HREs). Regardless, CNP-NPR-C signaling 
appears to represent a novel, innate angiogenic pathway independent of and equal 
magnitude to that proffered by VEGF (at least in assays described herein). 
The Gi-linked reparative action of CNP-NPR-C closely resembles the pro-angiogenic 
processes regulated by growth factors such as sphingosine-1-phosphate and insulin like 
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growth factor43, 44, both of which signal via single transmembrane domain Gi-coupled 
receptors. Thus, the present study suggests NPR-C, which similarly belongs to this 
‘atypical’ type 1 membrane GPCR family, can also be considered to function as a growth 
factor receptor in the context of angiogenesis (in contrast to more acute, functional changes 
in vascular tone and blood pressure10). Furthermore, we provide compelling evidence that 
CNP-NPR-C signaling is a widespread mechanism invoked to expedite tissue repair after 
injury. In two etiologically-distinct experimental models, wire-induced carotid damage and 
wound healing, recovery from insult was overtly impaired in animals endothelial CNP or 
global NPR-C null mutants. These more complex systems illustrate the significant 
contribution of CNP-NPR-C signaling to tissue repair and implicate additional roles above 
and beyond the processes of angiogenesis and arteriogenesis (the central focus of this 
study). Indeed, a previous report showed that pharmacological addition of CNP promotes 
angiogenesis in the skin of mice (albeit accompanied by slowed wound healing)45 and that 
CNP expression is up-regulated in human coronary atherosclerotic lesions46 and in the 
neointima following percutaneous coronary intervention47. These latter vasoprotective 
facets of CNP biology which drive vessel repair highlight the opposing effects of CNP on 
endothelial (stimulatory) and vascular smooth muscle/myofibroblast (inhibitory) proliferation. 
In turn, this may result from altered expression patterns of NPR-B and NPR-C on these 
cells; NPR-B is highly expressed in all cell types whereas NPR-C expression is higher on 
endothelial cells compared to vascular smooth muscle48. This dual activity may also 
underpin the more severe phenotype of global NPR-C-/-, versus ecCNP-/-, mice in these 
particular injurious experimental models. 
 In sum, endothelium-derived CNP plays a pivotal role in angiogenesis and vascular 
remodeling following ischemia via specific activation of NPR-C, Gi-stimulation, and 
triggering of ERK1/2 and PI3kγ/Akt/protein kinase B phosphorylation (Supplemental 
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Figure 10). Furthermore, pharmacological targeting of NPR-C promotes vascular repair 
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FIGURE LEGENDS 
Figure 1. C-type natrireutic peptide promotes angiogenesis in human umbilical vein 
endothelial cells via natriuretic peptide receptor-C. (A) C-type natriuretic peptide (CNP), 
natriuretic peptide receptor (NPR)-B and NPR-C mRNA expression is markedly reduced in 
gastrocnemius muscle biopsies of critical limb ischemia (CLI) patients compared to healthy subjects 
(Control; n=6-7), NPR-C protein levels are significantly reduced in gastrocnemius (B) myofibers and 
(C) blood vessels of CLI patients compared to healthy controls (cell membrane marker wheat germ 
agglutinin, WGA; endothelium specific marker, CD31; scale bars, 15 µm; n=6-7), (D) Representative 
images and (E) quantitative analysis showing that CNP (1 pM – 1 μM) accelerates human umbilical 
endothelial cell (HUVEC) migration (i.e. scratch closure) with a time-course similar to vascular 
endothelial growth factor (VEGF; 30 ng/mL) (n=6); (F) CNP (1 pM – 1 μM) promotes tubule 
formation in HUVECs with a maximal magnitude commensurate with VEGF (30 ng/mL) (n=4), (G & 
H) the NPR-C antagonist, M372049 (10 μM) and (I) NPR-C knockdown attenuates CNP (1 nM)-
induced tubule formation (scale bars, 100 µm; n=6). Data are presented as mean ± SEM. Statistical 
analyses by (A) Student’s t-test, (E) two-way ANOVA or (F, H & I) one-way ANOVA with Bonferoni 
post hoc test. *P<0.05, **P<0.01, ***P<0.001 versus healthy/control or #P<0.05, ###P<0.001 versus 
CNP alone. 
 
Figure 2. C-type natriuretic peptide increases scratch closure and tubule formation in murine 
pulmonary microvascular endothelial cells via natriuretic peptide receptor-C. (A) Migration 
(i.e. scratch closure) of murine pulmonary microvascular endothelial cells (PMEC) from wild type 
(WT) mice is facilitated by C-type natriuretic peptide (CNP; 1 nM) in a similar manner to vascular 
endothelial growth factor (VEGF; 30 ng/mL; n=6), (B) PMEC migration is impaired in cells from 
endothelium-specific CNP knockout (ecCNP-/-) mice compare to WT littermates (n=6), but (C) can 
be reversed by pharmacological addition of CNP (1 nM; n=6), (D) PMEC migration is arrested in 
cells from global natriuretic peptide receptor-C knockout (NPR-C-/-) but not global NPR-B-/- animals 
(n=6), (E & F) CNP (1 nM) augments PMEC migration in cells from NPR-B-/-, but not NPR-C-/- mice 
(n=6), (G & H) Intrinsic tubule forming capacity in PMEC is impaired in cells from ecCNP-/- and 
NPR-C-/-, but not NPR-B-/-, mice whereas CNP (1 nM) promotes tubule formation in WT, ecCNP-/- 
and NPR-B-/- PMEC but is unable to do so in NPR-C-/- cells (scale bars, 100 µm; n=12-15). Data are 
presented as mean ± SEM. Statistical analyses by (A-F) two-way ANOVA or (G) one-way ANOVA 
with Bonferroni post hoc test.  *P<0.05, ***P<0.001 versus WT or absence of CNP (A-F), *P<0.05, 
***P<0.001 versus WT or #P<0.05 versus corresponding genotype in the absence of CNP (G). 
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Figure 3. Aortic sprouting and matrigel plug neovascularization is diminished in vessels 
lacking either endothelial C-type natriuretic peptide or natriuretic pepide receptor-C. (A-C) C-
type natriuretic peptide (CNP; 1 pM – 1 μM) promotes de novo vessel sprouting ex vivo with a 
maximal effect equivalent to that produced by vascular endothelial growth factor (VEGF; 30 ng/mL; 
n=10), whereas inherent vessel sprouting capacity is diminished in aortic rings from endothelium-
specific CNP knockout (ecCNP-/-) and global natriuretic peptide receptor-C knockout (NPR-C-/-), but 
not global NPR-B-/-, mice and the pro-angiogenic action of CNP (1 nM) is maintained in wild type 
(WT), ecCNP-/- and NPR-B-/- vessels but absent in NPR-C-/- aortae (n=6), (D) CNP (1 nM) facilitates 
neovascularisation of matrigel plugs in vivo in WT and ecCNP-/- mice but is unable to recapitulate 
this pro-angiogenic activity in NPR-C-/- animals (n=12), as interrogated by (E) hemoglobin content, 
(F) Hematoxylin and eosin (H&E; upper panel) and immunofluorescence (lower panel) staining of 
transverse sections of the excised matrigel plugs (DAPI nuclear stain, blue; endothelium marker 
isolectin B4, green; arrows denote overt endothelial staining; scale bars, 50 µm). Data are 
presented as mean ± SEM. Statistical analyses by one-way ANOVA with Bonferroni post hoc test. 
*P<0.05, **P<0.01 versus Control or WT and #P<0.05, ##P<0.01 versus corresponding genotype in 
the absence of CNP. 
 
Figure 4. C-type natriuretic peptide triggers extracellular signal-regulated kinase 1/2 and 
Akt/Protein kinase B phosphorylation via natriurertic peptide receptor-C-dependent Gi 
activation. (A) Tubule formation (n=6), (B) aortic sprouting (n=12) and (C) extracellular signal-
regulated kinase (ERK)1/2 phosphorylation (n=6) in response to C-type natriuretic peptide (CNP; 1 
nM) are inhibited by the selective ERK1/2 inhibitor PD90859 (10 μM), (D) basal (Control) ERK1/2 
phosphorylation in pulmonary microvascular endothelial cells (PMEC) from endothelium-specific 
CNP knockout (ecCNP-/-) mice is lower than wild type (WT) littermates but can be similarly 
increased by CNP (1 nM) in both genotypes (n=10), (E & F) CNP (1 nM)-driven ERK1/2 
phosphorylation is blocked by the selective natriuretic pepide receptor (NPR)-C antagonist 
M372049 (10 μM; n=7) and the selective Gi inhibitor pertussis toxin (PTx, 100 ng/mL; n=7), (G) 
Tubule formation and (H) aortic sprouting in response to CNP (1 nM) are blocked by the Akt/protein 
kinase B inhibitor wortmannin (100 nM) (n=12), (I) basal (Control) Akt/protein kinase B 
phosphorylation is lower in PMECs from ecCNP-/- and global NPR-C knockout (NPR-C-/-) mice 
compared to wild type (WT) littermates and CNP (1 nM) promotes Akt phosphorylation in WT and 
ecCNP-/-, but not NPR-C-/-, animals (n=5). Data are presented as mean ± SEM. Statistical analyses 
by one-way ANOVA with Bonferroni post hoc test. ***P<0.05 versus Control or #P<0.05, ##P<0.01 
versus CNP alone (A-C, E-H), *P<0.05, **P<0.01 versus WT and #P<0.05, ###P<0.001 versus 
corresponding genotype in the absence of CNP (D & I). 
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Figure 5. Restoration of blood flow following hindlimb ischemia is impaired in endothelium-
specific C-type natriuretic peptide (CNP) knockout mice but can be reversed by 
pharmacological administration of CNP. (A) The mRNA expression of C-type natriuretic peptide 
(CNP) is reduced in ischemic gastrocnemius muscles (HLI) from wild type (WT) mice, compared to 
non-ischemic controls (Control), with a significant increase at day 7 following HLI (n=5-7), (B & C) 
Restoration of leg blood flow is impaired in endohelium-specific CNP knockout (ecCNP-/-) mice 
compared to WT littermates but can be phenotypically-rescued by administration of CNP 
(0.2mg/kg/day; n=6-12), (D & E) Reduction in capillary density (representative images showing 
immunostaining with DAPI nuclear stain, blue, endothelium marker isolectin B4, green, cellular 
membrane marker wheat germ agglutinin, red; scale bars, 50 µm), (F & G) increased fibrotic burden 
(representative images of collagen-specific Picrosirius staining; scale bars, 50 μm), and (H & I) 
impaired regeneration of muscle fibers (representative images of haematoxylin & eosin [H&E] 
staining; scale bars, 50 μm) are all exacerbated in ecCNP-/- mice compared to WT littermates but 
this phenotypic deficit is significantly reversed by addition of CNP (0.2mg/kg/day; n=6-12). Data are 
presented as mean ± SEM. Statistical analyses by (A & B) two-way ANOVA or (D, F & H) one-way 
ANOVA with Bonferroni post hoc test. *P<0.05, **P<0.01. ***P<0.001 versus WT or #P<0.05, 
##P<0.01, P<0.001 versus ecCNP-/- + CNP alone (A & B), *P<0.01, ***P<0.001 versus 
corresponding control genotype or ##P<0.01 versus WT HLI (C-E). 
 
Figure 6. Restoration of blood flow following hindlimb ischemia is impaired in global 
natriuretic peptide receptor-C knockout mice but cannot be rescued by pharmacological 
administration of C-type natriuretic peptide. (A) The mRNA expression of natriuretic peptide 
receptor (NPR)-C is reduced in ischemic gastrocnemius muscles (HLI) from wild type (WT) mice, 
compared to non-ischemic controls (Control), with a significant increased at day 7 following HLI 
(n=5-7), (B & C) Restoration of leg blood flow is impaired in global natriuretic peptide receptor-C 
knockout (NPR-C-/-) mice compared to WT littermates but is not amenable to phenotypic rescue by 
administration of C-type natriuretic peptide (CNP; 0.2mg/kg/day; n=6-12), (D & E) Reduction in 
capillary density (representative images showing immunostaining with DAPI nuclear stain, blue, 
endothelium marker isolectin B4, green, cellular membrane wheat germ agglutinin, red; scale bars, 
50 µm), (F & G) increased fibrotic burden (representative images of collagen-specific Picrosirius 
staining; scale bars, 50 μm), and (H & I) impaired regeneration of muscle fibers (representative 
images of haematoxylin & eosin [H&E] staining; scale bars, 50 μm) are all exacerbated in NPR-C-/- 
mice compared to WT littermates and this phenotypic deficit cannot be reversed by addition of CNP 
(0.2mg/kg/day; n=6-12). Data are presented as mean ± SEM. Statistical analyses by (A & B) two-
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way ANOVA or (D, F & H) one-way ANOVA with Bonferroni post hoc test. *P<0.05, **P<0.01. 
***P<0.001 versus WT or #P<0.05, ##P<0.01, ###P<0.001 versus ecCNP-/- + CNP alone (A & B), 
*P<0.01, ***P<0.001 versus corresponding control genotype or ##P<0.01 versus WT HLI (C-E). 
 
Figure 7. Reponses to vessel injury and wound healing in vivo are impaired in endothelium-
specific C-type natriuretic peptide knockout and global natriuretic peptide receptor-C 
knockout mice. (A-C) Neointimal hyperplasia (intima:media ratio) in response to wire injury in the 
carotid artery is exacerbated in endothelium-specific C-type natriuretic peptide knockout (ecCNP-/-) 
and global natriuretic peptide receptor-C knockout (NPR-C-/-) mice compared to wild type (WT) 
littermates (n=6-7). Representative images showing hematoxylin & eosin (H&E) staining, 
immunostaining with alpha smooth muscle actin (brown; panels 1-3, scale bar, 100µm) and 
immunofluorescence with DAPI nuclear stain (blue) and endothelium marker isolectin B4 (green; 
arrows denote overt endothelial staining; panels 4 & 5, scale bars, 50µm and 20µm, respectively). 
Wound healing (% closure) is impaired in (D & E) ecCNP-/- and (F & G) NPR-C-/- mice compared to 
WT littermates (n=9-13). Data are presented as mean ± SEM. Statistical analyses by (B & C) one-
way ANOVA with Bonferroni post hoc test or (D, F & H) two-way ANOVA. *P<0.05, ***P<0.001 
versus corresponding genotype uninjured and #P<0.05 versus WT injured (A) or *P<0.05, **P<0.01 
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Endothelium-specific CNP-/- were developed in house1, global NPR-B-/- 
(Peewee)2 were the kind gift of Prof. S. Camper (University of Michigan), and global 
NPR-C-/-3 were the kind gift of Prof. O. Smithies (University of North Carolina). Mice 
were housed in a climatically controlled environment, on a 12 h light/dark cycle, with 
free access to water and standard food ad libitum. 
 
Clinical samples 
All patients involved in the study were provided with written and verbal 
information prior to consenting. Patients undergoing above or below knee 
amputation for CLI secondary to PAD at the Royal Free Hospital were identified and 
consented. Immediately after limb amputation, the deep belly of the gastrocnemius 
muscle was identified on the amputated remnant and a 1 cm3 biopsy excised. 
Control samples were taken from consented patients undergoing coronary artery 
bypass graft without PAD (ankle-branchial index = 1.0 to 1.4) at St Bartholomew’s 
Hospital. During open saphenous vein harvesting, the deep belly of the 
gastrocnemius was identified and a 0.5cm3 muscle biopsy was excised. Upon 
collection, tissue was immediately divided in to two portions for further analysis. One 
portion was fixed in 10% formal saline containing 4% formaldehyde (CellStor Pot, 
CellPath Ltd, UK) prior to dehydrating for subsequent embedding and 
immunohistochemical analysis. A second portion was collected and treated with an 
RNA stabilizer (RNAlater, Sigma, UK) and stored at -20°C before RNA isolation. 
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Natriuretic peptide receptor expression & immunoblotting 
RNA was extracted from cells and tissues using a mini RNA extraction kit 
(Qiagen, UK) and quantified using a NanoDrop spectrophotometer (Thermo 
Scientific, MA, USA). RNA was subsequently converted to cDNA by reverse 
transcription (Quantitect Reverse Transcription kit, Qiagen, UK). For cells, 20 ng of 
cDNA from each sample was added to NPR-C and NPR-B Taqman gene expression 
assays and was amplified using quantitative real-time PCR over 40 cycles. For both 
human and mouse tissue samples, 10ng of cDNA from each sample was used for 
qPCR using a SYBR-green based PCR mix (SensiFast SYBR NO ROX; Bioline, UK) 
and primers from the specific gene of interest, followed by PCR in the thermal cycler 
(CFX Connect Realtime System, Biorad, UK) over 39 cycles. Samples were 
subjected to melting curve analysis to confirm amplification specificity. mRNA 
expression was analyzed by expressing the cycle threshold (Ct) value as 2-ΔΔCt, 
relative to the levels of RPL19 for tissue samples and GAPDH for cells, and further 
normalized as a fold change to control treatments. Primer sequences are provided in 
Supplemental Table 1. 
Standard sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) protocols were employed to identify protein expression using the following 
antibodies: NPR-C (1:500; Abcam), p42/44 MAPK (ERK1/2, 1:1000, 4696S), 
phosphor-p42/44 MAPK (p-ERK1/2, 1:1000, 9101S), Akt (1:1000), phosphor-Akt 
(1:1000; all Cell Signaling Technology, MA, USA). GAPDH (1:4000, AM4300; 
ThermoFisher Scientific, Hemel Hempstead, UK) or β-actin (1:5000; Millipore, UK) 
was used as loading control. 
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Histological and immunofluorescence analysis 
Gastrocnemius muscles were harvested from ischemic and non-ischemic 
limbs of all animals at 28 days following HLI, and from control and HLI patients fixed 
in 4% paraformaldehyde (overnight, 4°C). Following routine paraffin wax embedding, 
transverse sections (6 µm) were prepared using a microtome onto poly-L-lysine 
slides. Sections were allowed to dry overnight and stained with H&E for histological 
analysis. The proportion of fibers with central nuclei (regenerating fibers) was 
counted in the cross-sectional areas from both the injured and non-injured areas of 
both limbs, in a blinded fashion.  
Picrosirius red (0.1 % w/v) staining was used to visualize collagen fibers in the 
muscle and fibrosis was assessed blindly (Picrosirius Red Stain kit; Polysciences, 
Inc. Warrington, PA, USA). All slides were imaged using a Panoramic 250 High 
Throughput Scanner (3DHistech Ltd, Budapest, Hungary) and images were taken at 
x20 magnification using Panoramic Viewer software (Version 1.15.4, Budapest, 
Hungary) for analysis using Image J software (NIH, USA). 
Conjugated wheat germ agglutinin (WGA; wheat germ agglutinin, CF488A; 
Biotium, Cambridge, UK) staining was applied to outline muscle boundaries and 
isolectin B4 (IB4, Vector B-1205, Vector Laboratories Ltd., Peterborough, UK) for 
capillaries. All slides were imaged using the confocal microscope LSM510 (Carl 
Zeiss, Germany) and images were captured at x20 magnification for analysis using 
Image J software (NIH, USA). Number of capillaries per muscle fibre was manually 
counted in a blinded fashion.  
Immunofluorescence was used to localize NPR-C (anti-NPR-C, ab37617, 
1:100; Abcam), in the blood vessels using anti-CD31 (platelet endothelial cell 
adhesion molecule, PECAM-1, ab9498, Abcam, 1:20) and in the gastrocnemius 
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muscle using WGA (RL-1022, Vectorlabs, 1:50). Following routine removal of 
paraffin and antigen retrieval using citrate-based solution (pH6.0, Vectorlabs, UK), 
human gastrocnemius muscle sections were permeabilized for 10 min in 0.2% Triton 
X-100, in blocking solution (10% goat serum/1% bovine serum albumin (BSA) in 
PBS) at room temperature for 1 h and probed with the primary antibodies diluted in 
the blocking solution overnight at 4°C. After primary antibody incubation, sections 
were washed with PBS for three times and incubated with appropriate Alexa Fluor-
coupled secondary antibodies (1:400, Molecular Probes) for 1 h at room 
temperature. To counteract auto-fluorescence, sections were incubated in 0.3% 
Sudan black. Nuclei were counterstained with DAPI. Sections were thoroughly 
washed with PBS before mounting them with ProLong mounting media 





Supplemental Figure 1. Knockdown of natriuretic peptide receptor (NPR)-B and NPR-C in human umbilical vein endothelial cells. Relative expression of natriuretic peptide receptor (NPR)-C (A) mRNA and (B) protein, and NPR-B mRNA (C) in human umbilical vein endothelial cells (HUVEC) following siRNA knockdown (KD) in comparison to administration of a nonsensical RNA sequence (NS) demonstrating effective gene deletion. (D) C-type natriuretic peptide (CNP; 1 nM) promotes tubule formation in HUVECs in the absence and presence of NPR-B KD. Data are presented as mean ± SEM. Statistical analyses by Student’s t-test (A-C) and one-way ANOVA with Bonferroni post hoc test (D) with *P<0.05, **P<0.01, ***P<0.001 versus NS siRNA (n=5).   
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Supplemental Figure 3. Changes in natriuretic peptide receptor-C expression in human critical limb ischemia patients and murine hindlimb ischemia (A) Natriuretic peptide receptor (NPR)-C protein expression is markedly reduced in gastrocnemius muscle biopsies of critical limb ischemia (CLI) patients compared to healthy subjects (Control; n=6-7), and (B) NPR-C protein is reduced in ischemic gastrocnemius muscles (HLI) from wild type (WT) mice at day 3, compared to non-ischemic controls (Control), with a significant increase at day 7 following HLI (n=5-7). Data are presented as mean ± SEM. Statistical analyses by (A) Student’s t-test and (B) one-way ANOVA with Bonferroni post hoc test with *P<0.05, ***P<0.001 versus control or WT.  
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Supplemental Figure 4. Tubule formation in human umbilical vein endothelial cells is impaired by genetic or pharmacological blockade of C-type natriuretic peptide/natriuretic peptide receptor-C signalling. Tubule formation in human umbilical vein endothelial cells (HUVEC) is (A) promoted by vascular endothelial growth factor (VEGF; 30 ng/mL) in the presence and absence of endothelium-derived C-type natriuretic peptide (CNP) or natriuretic peptide receptor (NPR)-C, and (B) stimulated by the selective NPR-C agonist cANF4-23 (1 nM) and blocked by the selective NPR-C antagonist M372049 (10 μM), Data are presented as mean ± SEM. Statistical analyses by one way ANOVA with Bonferroni post hoc test with **P<0.01, ***P<0.001 versus corresponding control or genotype and ###P<0.001 versus cANF4-23 alone (n=6).  





















Supplemental Figure 5. Atrial natriuretic peptide does not trigger natriuretic peptide receptor-C-dependent angiogenic responses. Tubule formation in human umbilical vein endothelial cells (HUVEC) is promoted by atrial natriuretic peptide (ANP; 10 nM) but this is not blocked by the selective natriuretic peptide receptor (NPR)-C antagonist M372049 (10 μM). Data are presented as mean ± SEM. Statistical analyses by one way ANOVA with Bonferroni post hoc test with ***P<0.001 versus control (n=6).  

















Supplemental Figure 6. C-type natriuretic peptide facilitates endothelial cell migration in a concentration-dependent manner. C-type natriuretic peptide (CNP; 1 pM-1 nM) increases wild type (WT) murine pulmonary microvascular endothelial cell (PMEC) migration (i.e. scratch closure). Statistical analyses by two-way ANOVA with *P<0.05, ***P<0.001 versus control (n=6).  
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Supplemental Figure 7. C-type natriuretic peptide promotes angiogenesis in vivo. C-type natriuretic peptide (CNP; 1 nM) facilitates neovascularisation of matrigel plugs in vivo in wild type (WT) and global natriuretic peptide receptor-B knockout (NPR-B-/-) mice as interrogated by hemoglobin content. Data are presented as mean ± SEM. Statistical analyses by one way ANOVA with Bonferroni post hoc test with *P<0.05 versus corresponding genotype in the absence of CNP (n=3-6). 











Supplemental Figure 8. In vitro angiogenic responses to C-type natriuretic peptide are dependent on phosphoinositide 3-kinase γ but not cGMP-dependent protein kinase. Tubule formation in human umbilical vein endothelial cells (HUVEC) and aortic sprouting is (A & B) sensitive to the selective phosphoinositide 3-kinase (PI3K)γ inhibitor AS605240 (AS; 100nM) but (C & D) insensitive to the selective cGMP-dependent protein kinase (PKG) inhibitor KT5823 (2 μM). Statistical analyses by one way ANOVA with Bonferroni post hoc test with ***P<0.001 versus control and ###P<0.001 versus CNP alone (n=6).   





































Supplemental Figure 9. C-type natriuretic peptide (CNP) reverses the impaired recovery of blood flow following hindlimb ischemia in endothelium-specific CNP knockout, but not global natriuretic peptide receptor-C knockout, mice. Restoration of plantar blood flow is impaired in (A) endothelium-specific C-type natriuretic peptide knockout (ecCNP-/-) mice and (B) global natriuretic peptide receptor-C knockout (NPR-C-/-) animals compared to wild type (WT) littermates but this deficit can only be phenotypically-rescued by administration of CNP (0.2mg/kg/day) in ecCNP-/- mice Data are presented as mean ± SEM. Statistical analyses by two-way ANOVA with **P<0.01 versus WT and ##P<0.01 versus WT + CNP (n=6-12).  
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Supplemental Figure 10. Schematic representation of the novel CNP/NPR-C/Gi-triggered pro-angiogenic signaling pathways identified and characterized herein. C-type natriuretic peptide, CNP; natriuretic peptide receptor-C, NPR-C; G-protein subunits, αiβγ; mitogen-activated protein kinase, MAPK; extracellular signal-regulated kinase 1/2, ERK1/2; phosphoinositide 3-kinase γ, PI3Kγ.   
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SUPPLEMENTAL TABLE 
Target gene Primer sequence (5’-3’) Accession number 
Human Bax Forward: CGGGTTGTCGCCCTTTTCTA Reverse: GGACATCAGTCGCTTCAGTG NM_001291428.1 
Mouse Bax Forward: TGCAGAGGATGATTGCTGACG Reverse: AGCCACCCTGGTCTTGGAT NM_007527.3 
Human CNP Forward: TACAAAGGAGCCAACAAGAAGG Reverse: AAAGATGACCTCAGCACAACG NM_024409.3 
Mouse CNP Forward: AAAAGGGTGACAAGACTCCAGGCAG Reverse: GGTGTTGTGTATTGCCAGTA NM_010933.5 
Human CCL2 Forward: CTCAGCCAGATGCAATCAATG Reverse: TGAACCCACTTCTGCTTGGG NM_002982.3 
Mouse CCL2 Forward: GAAGCTGTAGTTTTTGTCACCA Reverse: TTCCTTCTTGGGGTCAGCAC NM_011333.3 
Human HIF-1α Forward: ATCACCCTCTTCGTCGCTTC Reverse: TCCAAATCACCAGCATCCAGAA NM_181054.2 
Mouse HIF-1α Forward: TCTGGATGCCGGTGGTCTA Reverse: AAAAAGCTCCGCTGTGTGTT NM_001313920.1 
Human IL-6 Forward: GGTACATCCTCGACGGCATC Reverse: CACCAGGCAAGTCTCCTCAT NM_000600.4 
Mouse IL-6 Forward: TCGTGGAAATGAGAAAAGAGTTGTG Reverse: ACTCCAGAAGACCAGAGGAAA NM_001314054.1 
Human NPR-B Forward: ACGGGCGCATTGTGTATATC Reverse: GGGCTCTTATCAGCAGACGA NM_003995.3 
Mouse NPR-B Forward: CCCTGTGCCTTTGACTTGGA Reverse: GCAACAACATTTCCCAGCGA NM_001355466.1 
Human NPR-C Forward: TTGCACACGTCCATCTACAGT Reverse: CTCTTCCATGAGCCATCTCCATA NM_001204375.1 
Mouse NPR-C Forward: GGGGGTCCACGAGGTTTTTC NM_008728.2 
16  
Reverse: CTCCACGAGCCATCTCCGTA 
Human VCAM-1 Forward: GGATAATGTTTGCAGCTTCTCAAG Reverse: TTCGTCACCTTCCCATTCAGT NM_001078.3 
Mouse VCAM-1 Forward: TGGTGAAATGGAATCTGAACC Reverse: CCCAGATGGTGGTTTCCTT NM_011693.3 
Human VEGF-A Forward: TGTGAATGCAGACCAAAGAAAG Reverse: ACCAACGTACACGCTCCAG NM_001025366.2 
Mouse VEGF-A Forward: GCAGATGTGAATGCAGACCAA Reverse: TTCTCCGCTCTGAACAAGGC NM_001110267.1 
Human VEGFR2 Forward: TCTGCCTACCTCACCTGTTTC Reverse: TGTCCGTCTGGTTGTCATCTG NM_002253.3 
Mouse VEGFR2 Forward: CATACCGCCTCTGTGACTTCT Reverse: GCTGTCCCCTGCAAGTAATCT NM_010612.2 






Supplemental Table 1. Primer sequences used for qRT-PCR analyses. C-type natriuretic peptide, CNP; chemokine (C-C motif) ligand 2, CCL2; hypoxia inducible factor-1α, HIF-1α; interleukin-6, IL-6; natriuretic peptide receptor-B, NPR-B; natriuretic peptide receptor-C, NPR-C; vascular cell adhesion molecule-1, VCAM-1; vascular endothelial growth factor-A, VEGF-A; VEGF receptor 2, VEGFR2; ribosomal protein L19, RPL19.   
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